<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87211">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969799</url>
  </required_header>
  <id_info>
    <org_study_id>CAP-01-102</org_study_id>
    <secondary_id>2013-002855-13</secondary_id>
    <nct_id>NCT01969799</nct_id>
  </id_info>
  <brief_title>Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia</brief_title>
  <acronym>IASIS</acronym>
  <official_title>A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardeas Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardeas Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin fosfomycin
      inhalation system (AFIS) versus aerosolized placebo to treat Gram-negative pneumonia in
      mechanically ventilated patients receiving IV antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate the safety and efficacy of the amikacin
      fosfomycin inhalation system (AFIS). AFIS consists of amikacin solution and fosfomycin
      solution, delivered by aerosol to the lungs via the PARI Investigational eFlow Inline System
      (eFlow Inline System). All patients will receive a standardized course of intravenous (IV)
      antibiotics for a minimum of 7 days. Patients will be randomized to receive 10 days of
      treatment with either AFIS or placebo, in addition to the IV therapy. The primary efficacy
      endpoint is defined as the change from baseline in the Clinical Pulmonary Infection Score
      (CPIS) during the randomized course of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinical Pulmonary Infection Score (CPIS) during the planned 10-day treatment period.</measure>
    <time_frame>10 day treatment period.</time_frame>
    <description>Daily CPIS will be determined by one blinded, central reviewer in order to minimize inter-observer variability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of mortality and clinical cure</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>The hierarchical composite endpoint of mortality, then clinical cure (defined as both absence of Gram-negative bacteria and CPIS at Day 14 &lt; 6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of mortality and ventilator-free days</measure>
    <time_frame>Day 1- Day 28</time_frame>
    <description>The hierarchical composite endpoint of mortality, then ventilator-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days free of mechanical ventilation from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU days from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rates in patients positive for multi-drug resistant Gram-negative bacteria</measure>
    <time_frame>Day 14</time_frame>
    <description>Microbiological response rates at Day 14 in patients whose pre-study treatment bronchoalveolar lavage (BAL) was positive for multi-drug resistant Gram-negative bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse rate</measure>
    <time_frame>Day 11 - Day 28</time_frame>
    <description>Clinical relapse rates (defined as a new episode of pneumonia requiring reinstitution of IV antibiotics) from Day 11 through Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>Amikacin fosfomycin inhalation solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin fosfomycin inhalation solution</intervention_name>
    <description>300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System</description>
    <arm_group_label>Amikacin fosfomycin inhalation solution</arm_group_label>
    <other_name>Amikacin fosfomycin inhalation system (AFIS)</other_name>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized placebo</intervention_name>
    <description>Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System</description>
    <arm_group_label>Aerosolized placebo</arm_group_label>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females, ≥ 18 years and ≤ 80 years of age

          -  Intubated and mechanically ventilated

          -  Diagnosis of pneumonia, defined as presence of a new or progressive infiltrate(s) on
             the most recent chest radiograph prior to screening, as determined by the treating
             physician

          -  Signs of infection (within 24 hours prior to screening):

               1. Fever (&gt; 38ºC or &gt; 100.4ºF); or

               2. Leukopenia (&lt; 4,000 WBC/mm3) or leukocytosis (≥ 12,000 WBC/mm3)

          -  Impaired oxygenation (within 24 hours prior to screening):

             a. PaO2/FiO2 ≤ 350 mmHg

          -  Acute Physiology and Chronic Health Evaluation (APACHE) II score &gt; 10 (within 24
             hours prior to screening)

          -  Presence, or high suspicion, of Gram-negative organism(s) by either Gram stain or
             culture of respiratory secretions from a sample obtained within the previous 7 days
             (enrollment can occur before culture results are available)

        Exclusion Criteria:

          -  History of hypersensitivity to amikacin, other aminoglycosides, fosfomycin, imipenem,
             meropenem, or colistin

          -  Received systemic antibiotic therapy for this episode of Gram-negative pneumonia for
             greater than 72 hours at the time of randomization

          -  PaO2/FiO2 ≤ 100 mmHg and diffuse infiltrates on Chest X-ray

          -  Refractory septic shock (severe sepsis plus unstable hypotension, in spite of
             adequate fluid resuscitation and vasopressors)

          -  Any of the following conditions that interfere with the assessment or interpretation
             of the diagnosis or response to therapy:

               1. chest trauma with ongoing loss of stability of the thoracic cage following a
                  fracture of the sternum, ribs, or both;

               2. increased amounts of fluid in the lung cavities requiring chest tube drainage;

               3. lung cancer within the last 2 years;

               4. lung abscess(s);

               5. anatomical bronchial obstruction;

               6. suspected atypical pneumonia;

               7. chemical pneumonitis (e.g., inhalation injury);

               8. cystic fibrosis

          -  Immunocompromised patients, including those with neutropenia NOT due to the current
             infection (absolute neutrophil count &lt; 500/mm3), leukemia, lymphoma, human
             immunodeficiency virus (HIV) infection with CD4 count &lt; 200 cells/mm3, or
             splenectomy; those who are early post-transplantation (&lt; 3 months post-transplant, or
             &gt; 3 months post-transplant with evidence of organ rejection by clinical criteria,
             pathologic confirmation, or modification of immunosuppression within the past 4
             weeks), are on cytotoxic chemotherapy, or are on high-dose steroids (e.g., &gt; 40 mg of
             prednisone or its equivalent [&gt; 160 mg hydrocortisone, &gt; 32 mg methylprednisolone, &gt;
             6 mg dexamethasone, &gt; 200 mg cortisone] daily for &gt; 2 weeks)

          -  Evidence of significant renal impairment (serum creatinine &gt; 4.0 mg/dL within 24
             hours prior to screening). If serum creatinine is &gt;2.0 mg/dL, site must be capable of
             performing continuous renal replacement therapy, if clinically indicated. Patients
             with serum creatinine &gt; 4.0 mg/dL and being treated with continuous renal replacement
             therapy (continuous venous-venous hemofiltration or continuous venous-venous
             hemodialysis) or chronic hemodialysis are eligible

          -  Evidence of ototoxicity (history of hearing aid use prior to current hospitalization)

          -  Evidence of hepatotoxicity (alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] &gt;3X the upper limit of normal value within 24 hours prior to
             screening)

          -  Positive urine and/or serum beta-hCG pregnancy test (only in women of reproductive
             age)

          -  On mechanical ventilation for &gt; 28 days

          -  Glasgow Coma Scale score =3 at Screening

          -  Participating in or has participated in other investigational interventional studies
             (drug or device) within the last 30 days (or 5 times the half-life of the previously
             administered investigational compound, whichever is longer) prior to study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin Kollef, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>21686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>60198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <state>Limousin</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colombes</city>
        <state>Île-de-France</state>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>15227</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41334</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1081</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Comunidad de Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anakara</city>
        <state>Ankara</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/antibiotics.html</url>
    <description>MedlinePlus related topics: Antibiotics</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/pneumonia.html</url>
    <description>MedlinePlus related topics: Pneumonia</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0037517285&amp;QV1=AMIKACIN</url>
    <description>Drug Information available for amikacin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0023155024&amp;QV1=FOSFOMYCIN</url>
    <description>Drug information available for fosfomycin</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>May 9, 2016</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-negative pneumonia</keyword>
  <keyword>Aerosol antibiotics</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Fosfomycin</keyword>
  <keyword>Pneumonia, Bacterial</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
